References
  1. Zipes DP, DiMarco JP, Jackman WM, et al. ACC/AHA Task Force Report: Guidelines for Clinical Intracardiac Electrophysiological and Catheter Ablation Procedures. J Am Coll Cardiol. 1995;26(2):555-573.
  2. D’Silva A, Wright M. Advances in imaging for atrial fibrillation ablation. Radiol Res Pract. 2011;2011:714864.
  3. Tuttle RR, Mills J. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res. 1975; 36(1):185-196.
  4. Vanegas DI, Perez C de J, Montenegro J de J, et al. Dobutamine use for arrhythmia induction during electrical programmed heart stimulation. Rev Colomb Cardiol. 2006;12(7):479-483.
  5. Cossú SF, Rothman SA, Chmielewski IL, Hsia HH, Vogel RL, Miller JM, Buxton AE. The effects of isoproterenol on the cardiac conduction system: site-specific dose dependence. J Cardiovasc Electrophysiol. 1997 Aug;8(8):847-53. doi: 10.1111/j.1540-8167.1997.tb00845.x. PMID: 9261710.
  6. Knight BP. The rising costs of isoproterenol. EP Lab Dig. 2013 Mar;17(3).
  7. Khot UN, Vogan ED, Militello MA. Nitroprusside and Isoproterenol Use after Major Price Increases. N Engl J Med. 2017 Aug 10;377(6):594-595. doi: 10.1056/NEJMc1700244. PMID: 28792879.
  8. Cismaru G. Arrhythmia induction in the EP lab. 1sted. Cham, Switzerland: Springer Nature Switzerland AG;2019:71-86.
  9. Gianni C, Sanchez JE, Mohanty S, Trivedi C, Della Rocca DG, Al-Ahmad A, Burkhardt JD, Gallinghouse GJ, Hranitzky PM, Horton RP, Di Biase L, Natale A. High-Dose Dobutamine for Inducibility of Atrial Arrhythmias During Atrial Fibrillation Ablation. JACC Clin Electrophysiol. 2020 Dec 14;6(13):1701-1710. doi: 10.1016/j.jacep.2020.07.018. Epub 2020 Sep 30. PMID: 33334450.
  10. Piérard LA, Berthe C, Albert A, Carlier J, Kulbertus HE. Haemodynamic alterations during ischaemia induced by dobutamine stress testing. Eur Heart J. 1989 Sep;10(9):783-90. doi: 10.1093/oxfordjournals.eurheartj.a059571. PMID: 2806276.
  11. Lu D, Greenberg MD, Little R, Malik Q, Fernicola DJ, Weissman NJ. Accelerated dobutamine stress testing: safety and feasibility in patients with known or suspected coronary artery disease. Clin Cardiol. 2001 Feb;24(2):141-5. doi: 10.1002/clc.4960240208. PMID: 11214744; PMCID: PMC6654775.
  12. Mazeika PK, Nadazdin A, Oakley CM. Dobutamine stress echocardiography for detection and assessment of coronary artery disease. J Am Coll Cardiol. 1992 May;19(6):1203-11. doi: 10.1016/0735-1097(92)90325-h. PMID: 1564221.
  13. Burger AJ, Notarianni MP, Aronson D. Safety and efficacy of an accelerated dobutamine stress echocardiography protocol in the evaluation of coronary artery disease. Am J Cardiol. 2000 Oct 15;86(8):825-9. doi: 10.1016/s0002-9149(00)01100-0. PMID: 11024395.
  14. Masoni A, Alboni P, Malacarne C, Codeca L. Effects of dobutamine on electrophysiological properties of the specialized conduction system in man. J Electrocardiol. 1979 Oct;12(4):361-70. doi: 10.1016/s0022-0736(79)80004-7. PMID: 512532.
  15. Hariman, Robert J, Gomes, Joseph, El-Sharif, N. Catecholamine-dependent Atrioventricular Nodal Reentrant Tachycardia. Circulation 1983;67(3):1983.
Figure Legends.
Figure 1. Demonstrates the relative decrease in sinus cycle length from baseline to 5 mcg/kg/min, 10 mcg/kg/min, 15 mcg/kg/min and 20 mcg/kg/min of dobutamine.
Figure 2. Demonstrates the relative decrease in AVNBCL and VABCL from baseline to 5 mcg/kg/min, 10 mcg/kg/min, 15 mcg/kg/min and 20 mcg/kg/min of dobutamine.
Figure 3. Demonstrates the relative decrease in AH interval from baseline to 5 mcg/kg/min, 10 mcg/kg/min, 15 mcg/kg/min and 20 mcg/kg/min of dobutamine.
Figure 4. Demonstrates the relative change in HV interval from baseline to 5 mcg/kg/min, 10 mcg/kg/min, 15 mcg/kg/min and 20 mcg/kg/min of dobutamine.
Figure 5. Demonstrates the relative change in QRS duration and QT interval from baseline to 5 mcg/kg/min, 10 mcg/kg/min, 15 mcg/kg/min and 20 mcg/kg/min of dobutamine.
Figure 6. Demonstrates the relative change in AERP, AVNERP and VERP from baseline to 5 mcg/kg/min, 10 mcg/kg/min, 15 mcg/kg/min and 20 mcg/kg/min of dobutamine.
Figure 7. Demonstrates the relative change in diastolic blood pressure and systolic blood pressure from baseline to 5 mcg/kg/min, 10 mcg/kg/min, 15 mcg/kg/min and 20 mcg/kg/min of dobutamine.
Table 1. Patient Demographics and EP/Ablation Indications